ATE516297T1 - Mit copolymer 1 verwandte polypeptide zur verwendung als molekulargewichtsmarker und zur therapeutischen verwendung - Google Patents

Mit copolymer 1 verwandte polypeptide zur verwendung als molekulargewichtsmarker und zur therapeutischen verwendung

Info

Publication number: ATE516297T1
Authority: AT; Austria
Prior art keywords: molecular weight; weight markers; copolymer; copolymers; glatiramer acetate
Prior art date: 1998-09-25

Application number

AT09004306T

Other languages

English (en)

Inventor

Alexander Gad

Dora Lis

Original Assignee

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-25

Filing date

1999-09-24

Publication date

2011-07-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22285926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE516297(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-09-24 Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev

2011-07-15 Application granted granted Critical

2011-07-15 Publication of ATE516297T1 publication Critical patent/ATE516297T1/de

Links

229920001577 copolymer Polymers 0.000 title abstract 4
229920001184 polypeptide Polymers 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1
108010072051 Glatiramer Acetate Proteins 0.000 abstract 3
FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 abstract 3
229960003776 glatiramer acetate Drugs 0.000 abstract 3
230000004071 biological effect Effects 0.000 abstract 1
208000026278 immune system disease Diseases 0.000 abstract 1
230000014759 maintenance of location Effects 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Biochemistry (AREA)
Physical Education & Sports Medicine (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Obesity (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Pulmonology (AREA)

AT09004306T 1998-09-25 1999-09-24 Mit copolymer 1 verwandte polypeptide zur verwendung als molekulargewichtsmarker und zur therapeutischen verwendung ATE516297T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10169398P	1998-09-25	1998-09-25

Publications (1)

Publication Number	Publication Date
ATE516297T1 true ATE516297T1 (de)	2011-07-15

Family

ID=22285926

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT99949923T ATE431359T1 (de)	1998-09-25	1999-09-24	Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie
AT09004306T ATE516297T1 (de)	1998-09-25	1999-09-24	Mit copolymer 1 verwandte polypeptide zur verwendung als molekulargewichtsmarker und zur therapeutischen verwendung

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT99949923T ATE431359T1 (de)	1998-09-25	1999-09-24	Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie

Country Status (17)

Country	Link
EP (3)	EP2239269B1 (de)
JP (2)	JP4629229B2 (de)
AT (2)	ATE431359T1 (de)
AU (1)	AU757413B2 (de)
CA (2)	CA2794705C (de)
CY (3)	CY1110490T1 (de)
DE (2)	DE09004306T1 (de)
DK (3)	DK2239269T3 (de)
ES (3)	ES2327301T3 (de)
HU (3)	HU229719B1 (de)
IL (4)	IL142116A0 (de)
NO (2)	NO329877B1 (de)
NZ (1)	NZ511020A (de)
PT (3)	PT2090583E (de)
SI (1)	SI1115743T1 (de)
WO (1)	WO2000018794A1 (de)
ZA (1)	ZA200102269B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2527760T3 (es)	1998-07-23	2015-01-29	Yeda Research And Development Co., Ltd.	Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
IL141021A0 (en)	1998-07-23	2002-02-10	Yeda Res & Dev	Treatment of autoimmune conditions with copolymer 1 and related copolymers
US6800287B2 (en)	1998-09-25	2004-10-05	Yeda Research And Development Co., Ltd.	Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
ZA200206457B (en)	2000-02-18	2003-08-13	Yeda Res & Dev	Oral, nasal and pulmonary dosage formulations of copolymer 1.
US20020077278A1 (en)	2000-06-05	2002-06-20	Yong V. Wee	Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
IL148202A0 (en) *	2000-06-20	2002-09-12	Caprion Pharmaceuticals Inc	Copolymers and methods of treating prion-related diseases
WO2002076503A1 (en)	2000-06-20	2002-10-03	Mayo Foundation For Medical Education And Research	Treatment of central nervous system diseases by antibodies against glatiramer acetate
US20040037828A1 (en) *	2002-07-09	2004-02-26	Bar-Ilan University	Methods and pharmaceutical compositions for healing wounds
HUP0401863A3 (en) *	2001-10-03	2012-09-28	Harvard College	Amino acid-copolymers for suppression of autoimmune diseases, and methods of use
NZ533327A (en)	2001-12-04	2006-11-30	Teva Pharma	Processes for the measurement of the potency of glatiramer acetate
ZA200505733B (en)	2003-01-21	2006-10-25	Yeda Res & Dev	COP 1 for treatment of inflammatory bowel diseases
WO2005013885A2 (en)	2003-08-07	2005-02-17	Healor Ltd.	Pharmaceutical compositions and methods for accelerating wound healing
MXPA06010043A (es) *	2004-03-01	2007-03-07	Peptimmune Inc	Metodos y composiciones para el tratamiento de enfermedades autoinmunologicas.
US7655221B2 (en)	2004-05-07	2010-02-02	Peptimmune, Inc.	Methods of treating disease with random copolymers
ES2572811T3 (es)	2004-09-09	2016-06-02	Yeda Research And Development Co., Ltd.	Mezclas de polipéptidos, composiciones que las contienen y procedimientos para obtener los mismos, y usos de los mismos
US7858337B2 (en) *	2007-03-08	2010-12-28	Novartis Ag	Process for the manufacture of a composite material
EA019998B9 (ru)	2009-08-20	2016-01-29	Йеда Рисерч Энд Дивелопмент Ко. Лтд.	Терапия глатирамером ацетатом с низкой кратностью
USRE49251E1 (en)	2010-01-04	2022-10-18	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en)	2010-03-16	2014-06-24	Teva Pharmaceutical Industries, Ltd.	Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
PL2627669T3 (pl)	2010-10-11	2017-02-28	Teva Pharmaceutical Industries Ltd.	Biomarkery cytokinowe jako biomarkery prognostyczne odpowiedzi klinicznej na octan glatirameru
RU2604521C2 (ru)	2011-02-14	2016-12-10	Юсв Прайвит Лимитед	Сополимер-1, способы его получения и аналитические методы
EP2765857A4 (de)	2011-10-10	2015-12-09	Teva Pharma	Einzelnukleotidpolymorphismen zur vorhersage des klinischen ansprechens auf glatirameracetat
HK1213830A1 (zh)	2012-10-10	2016-07-15	Teva Pharmaceutical Industries Ltd.	用於预测醋酸格拉替雷临床反应的生物标志物
CN104098655B (zh) *	2013-04-09	2018-01-30	深圳翰宇药业股份有限公司	用于合成醋酸格拉替雷的质谱内标的多肽
UY35790A (es)	2013-10-21	2015-05-29	Teva Pharma	Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105218646B (zh) *	2014-06-24	2018-09-21	深圳翰宇药业股份有限公司	一种用于检测醋酸格拉替雷样本的uplc方法
US9155775B1 (en)	2015-01-28	2015-10-13	Teva Pharmaceutical Industries, Ltd.	Process for manufacturing glatiramer acetate product
CN112649538B (zh) *	2015-04-28	2024-03-29	深圳翰宇药业股份有限公司	多肽混合物高效液相色谱分析方法
ES2744179T3 (es)	2015-09-24	2020-02-24	Chemi Spa	Análisis de la distribución de peso molecular de mezclas de polipéptidos complejas
US12097292B2 (en)	2016-08-28	2024-09-24	Mapi Pharma Ltd.	Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en)	2016-08-31	2024-09-05	Mapi Pharma Ltd	Depot systems comprising glatiramer acetate
MX2019010174A (es)	2017-03-26	2019-10-15	Mapi Pharma Ltd	Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2009996A1 (en) *	1989-02-17	1990-08-17	Kathleen S. Cook	Process for making genes encoding random polymers of amino acids
US5800808A (en)	1994-05-24	1998-09-01	Veda Research And Development Co., Ltd.	Copolymer-1 improvements in compositions of copolymers

1999
- 1999-09-24 HU HU1300505A patent/HU229719B1/hu unknown
- 1999-09-24 DE DE09004306T patent/DE09004306T1/de active Pending
- 1999-09-24 HU HU0103889A patent/HU229289B1/hu unknown
- 1999-09-24 EP EP10171553A patent/EP2239269B1/de not_active Expired - Lifetime
- 1999-09-24 DK DK10171553.0T patent/DK2239269T3/da active
- 1999-09-24 SI SI9931035T patent/SI1115743T1/sl unknown
- 1999-09-24 PT PT09004306T patent/PT2090583E/pt unknown
- 1999-09-24 DK DK99949923T patent/DK1115743T3/da active
- 1999-09-24 EP EP99949923A patent/EP1115743B1/de not_active Expired - Lifetime
- 1999-09-24 CA CA2794705A patent/CA2794705C/en not_active Expired - Lifetime
- 1999-09-24 EP EP09004306A patent/EP2090583B1/de not_active Expired - Lifetime
- 1999-09-24 AT AT99949923T patent/ATE431359T1/de active
- 1999-09-24 ES ES99949923T patent/ES2327301T3/es not_active Expired - Lifetime
- 1999-09-24 DE DE69940888T patent/DE69940888D1/de not_active Expired - Lifetime
- 1999-09-24 CA CA2343929A patent/CA2343929C/en not_active Expired - Lifetime
- 1999-09-24 JP JP2000572252A patent/JP4629229B2/ja not_active Expired - Lifetime
- 1999-09-24 IL IL14211699A patent/IL142116A0/xx unknown
- 1999-09-24 PT PT101715530T patent/PT2239269E/pt unknown
- 1999-09-24 ES ES10171553T patent/ES2408706T3/es not_active Expired - Lifetime
- 1999-09-24 AU AU62695/99A patent/AU757413B2/en not_active Expired
- 1999-09-24 ES ES09004306T patent/ES2369642T3/es not_active Expired - Lifetime
- 1999-09-24 ZA ZA200102269A patent/ZA200102269B/en unknown
- 1999-09-24 HU HU1300337A patent/HU229720B1/hu unknown
- 1999-09-24 WO PCT/US1999/022402 patent/WO2000018794A1/en not_active Ceased
- 1999-09-24 NZ NZ511020A patent/NZ511020A/xx not_active IP Right Cessation
- 1999-09-24 AT AT09004306T patent/ATE516297T1/de active
- 1999-09-24 DK DK09004306.8T patent/DK2090583T3/da active
- 1999-09-24 PT PT99949923T patent/PT1115743E/pt unknown
2001
- 2001-03-20 IL IL142116A patent/IL142116A/en not_active IP Right Cessation
- 2001-03-21 NO NO20011441A patent/NO329877B1/no not_active IP Right Cessation
2009
- 2009-08-06 CY CY20091100835T patent/CY1110490T1/el unknown
2010
- 2010-03-25 NO NO20100442A patent/NO336685B1/no not_active IP Right Cessation
- 2010-06-23 JP JP2010142689A patent/JP4903886B2/ja not_active Expired - Lifetime
- 2010-11-07 IL IL209190A patent/IL209190A/en not_active IP Right Cessation
- 2010-11-07 IL IL209189A patent/IL209189A/en not_active IP Right Cessation
2011
- 2011-10-05 CY CY20111100947T patent/CY1112197T1/el unknown
2013
- 2013-04-15 CY CY20131100310T patent/CY1113932T1/el unknown

Also Published As

Publication number	Publication date
NZ511020A (en)	2003-06-30
NO20100442L (no)	2001-05-25
IL142116A (en)	2010-12-30
PT2239269E (pt)	2013-04-09
HU229720B1 (en)	2014-05-28
CY1113932T1 (el)	2016-07-27
HUP0103889A2 (hu)	2002-03-28
JP2002525378A (ja)	2002-08-13
CA2343929A1 (en)	2000-04-06
WO2000018794A1 (en)	2000-04-06
DK2239269T3 (da)	2013-04-29
EP2239269A1 (de)	2010-10-13
DK2090583T3 (da)	2011-09-12
AU6269599A (en)	2000-04-17
DK1115743T3 (da)	2009-07-27
NO336685B1 (no)	2015-10-19
CY1110490T1 (el)	2015-04-29
EP2239269B1 (de)	2013-01-16
CA2343929C (en)	2013-01-29
HU229719B1 (en)	2014-05-28
NO20011441L (no)	2001-05-25
HK1040521A1 (en)	2002-06-14
JP4629229B2 (ja)	2011-02-09
NO20011441D0 (no)	2001-03-21
CA2794705A1 (en)	2000-04-06
AU757413B2 (en)	2003-02-20
HK1149279A1 (en)	2011-09-30
EP2090583A1 (de)	2009-08-19
EP1115743A4 (de)	2005-04-27
HU229289B1 (en)	2013-10-28
IL209189A (en)	2017-11-30
CA2794705C (en)	2017-07-18
IL209190A0 (en)	2011-01-31
IL209189A0 (en)	2011-01-31
DE09004306T1 (de)	2010-12-09
ES2369642T3 (es)	2011-12-02
CY1112197T1 (el)	2015-12-09
EP1115743A1 (de)	2001-07-18
JP4903886B2 (ja)	2012-03-28
HUP0103889A3 (en)	2004-03-01
SI1115743T1 (sl)	2010-01-29
JP2010271325A (ja)	2010-12-02
EP1115743B1 (de)	2009-05-13
DE69940888D1 (de)	2009-06-25
ES2408706T3 (es)	2013-06-21
IL142116A0 (en)	2002-03-10
PT1115743E (pt)	2009-07-07
ZA200102269B (en)	2002-03-19
IL209190A (en)	2017-11-30
PT2090583E (pt)	2011-09-14
ATE431359T1 (de)	2009-05-15
NO329877B1 (no)	2011-01-17
HK1133021A1 (en)	2010-03-12
EP2090583B1 (de)	2011-07-13
ES2327301T3 (es)	2009-10-27

Legal Events

Date

Code

Title

Description

2012-04-15

UEP

Publication of translation of european patent specification

Ref document number: 2090583

Country of ref document: EP

Publication	Publication Date	Title
ATE516297T1 (de)	2011-07-15	Mit copolymer 1 verwandte polypeptide zur verwendung als molekulargewichtsmarker und zur therapeutischen verwendung
DK0397633T3 (da)	1996-01-02	Fibronectinbindende protein samt fremstilling deraf
DK0737207T3 (da)	2005-01-31	Inhibitorer for humant plasmin afledt af Kunitz-domæner
TR200001709T2 (tr)	2001-03-21	Yeni neisseria meningitids yüzey proteini
EE05497B1 (et)	2011-12-15	Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
ATE273031T1 (de)	2004-08-15	Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen
NO882380D0 (no)	1988-05-31	Fibfonektin-bindende protein, samt fremstilling derav.
DE3673217D1 (de)	1990-09-13	Phenylalkyl-2,3-dihydrobenzofurane und analoga zur verwendung als antientzuendungsmittel.
DK0845034T3 (da)	2003-06-30	Peptid med pronociceptive egenskaber
ATE271125T1 (de)	2004-07-15	Neuartige tyrosinkinase
ATE312179T1 (de)	2005-12-15	Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
EP0919621A4 (de)	2000-04-12	Menschliche tak1 und für diese kodierende dna
DE68906167D1 (de)	1993-06-03	Zusammensetzung zur erkennung von paradontalen krankheiten.
ATE242883T1 (de)	2003-06-15	Verfahren zur bestimmung von blutgerinnungsfaktoren viii und ix